- The P-III trial will assess adjuvanted CoVLP formulation (two doses of 3.75µg, administered 21 days apart) vs PBO in ~30,000 subjects initially in healthy adults (18-65yrs.), followed by elderly adults (65yrs.+) and adults with comorbidities
- The US FDA and Health Canada have approved the initiation of the P-III study based on the positive P-II results which are expected to be available in Apr’21.
- In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants. The US FDA has granted FTD to the vaccine on Feb 17, 2021
Click here to read full press release/ article | Ref: Businesswire | Image: ABC 11